| 現職： | – 中山醫學大學附設醫院感染科主治醫師 – 中山醫學大學醫學系助理教授 |
| 專長： | 常見傳染病的診斷與治療，例如：人體各部因細菌、病毒或其它病原體引起之感染 、各種原因引起之發燒及不明原因之發燒、感冒、扁桃腺炎、氣管炎、肺炎性病、梅毒、淋病、尿道炎、膀胱炎、腎盂炎、骨髓炎、蜂窩性組織炎、腦膜炎、腦炎、結核病、肺結核及愛滋病等 |
| 過去五年內執行臨床試驗案件數： | 1 件 |
| 近五年論文著作： | 《2025》李育霖、薛博仁 Expert Review of Anti-Infective Therapy 2025 Nov;23(11):1095-1117 An update on antimicrobial selection and duration for intra-abdominal infections 《2025》李育霖、郭書辰、楊雅頌 International journal of antimicrobial agents 2025 Sep;66(3):107550 In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022 《2025》李育霖、楊雅頌、郭書辰 Journal of Microbiology, Immunology and Infection 2025 Apr;58(2):219-225 Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel β-lactam/β-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020-2022 《2024》楊雅頌、李育霖、郭書辰 International Journal of Antimicrobial Agents 2024 Dec;64(6):107378 Acquired blaCfxA-3 carried by a conjugative transposon or duplicated intrinsic blaCME-3 mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates 《2024》賴怡琪、李育霖(通訊作者) International Journal of Antimicrobial Agents 2024 Nov;64(5):107342 Conversion of blaKPC-2 to blaKPC-33 leads to worldwide emergence of ceftazidime-avibactam resistance in Klebsiella pneumoniae 《2024》李育霖、薛博仁 Journal of Microbiology, Immunology and Infection 2024 Aug;57(4):523-532 Burden of respiratory syncytial virus in older adults in Taiwan: An expert perspective on knowledge gaps 《2024》李育霖、薛博仁 Journal of Antimicrobial Chemotherapy 2024 Jul 1;79(7):1581-1589. Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021 《2024》賴怡琪、李育霖(通訊作者) International Journal of Antimicrobial Agents 2024 May 23;64(2):107213. Emergence of ceftazidime-avibactam resistance through in-vivo blaKPC-2 to blaKPC-33 conversion during treatment of ST11 Klebsiella pneumoniae associated infections 《2024》李育霖、薛博仁 Journal of Microbiology Immunology and Infection 2024 Jun;57(3):446-456 Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021 《2023》李育霖、薛博仁 Current Opinion in Infectious Diseases 2023 Dec 1;36(6):481-494. Emerging infections in vulnerable hosts: Stenotrophomonas maltophilia and Elizabethkingia anophelis 《2023》李育霖、Po-Ren Hsueh International journal of antimicrobial agents 2023 Aug;62(2):106878 In vitro susceptibilities of Stenotrophomonas maltophilia isolates to antimicrobial agents commonly used for related infections: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2004-2020 《2023》李育霖、Po-Ren Hsueh International journal of antimicrobial agents 2023 Aug;62(2):106867 In vitro activities of ceftazidime–avibactam, ceftolozane–tazobactam, meropenem–vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012–2021 《2023》李育霖、Po-Ren Hsueh Journal of infection 2023 Jul;87(1):e1-e4 Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021 |